The US Centers for Medicare and Medicaid Services is proposing to broaden the pool of new prescription drugs for end-stage renal disease that are eligible for add-on reimbursement payments from Medicare.
The new policy is part of a proposed rule updating the Medicare end-stage renal disease (ESRD) prospective payment system for 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?